- Home
- TGTX vs ONTO Comparison
TGTX vs ONTO Comparison
Compare TGTX & ONTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- ONTO
- Stock Information
- Founded
- TGTX 1993
- ONTO 1940
- Country
- TGTX United States
- ONTO United States
- Employees
- TGTX N/A
- ONTO N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- ONTO Industrial Machinery/Components
- Sector
- TGTX Health Care
- ONTO Industrials
- Exchange
- TGTX Nasdaq
- ONTO Nasdaq
- Market Cap
- TGTX 4.2B
- ONTO 4.9B
- IPO Year
- TGTX 1995
- ONTO N/A
- Fundamental
- Price
- TGTX $29.45
- ONTO $108.51
- Analyst Decision
- TGTX Strong Buy
- ONTO Strong Buy
- Analyst Count
- TGTX 4
- ONTO 7
- Target Price
- TGTX $42.50
- ONTO $137.86
- AVG Volume (30 Days)
- TGTX 2.9M
- ONTO 1.5M
- Earning Date
- TGTX 08-04-2025
- ONTO 08-07-2025
- Dividend Yield
- TGTX N/A
- ONTO N/A
- EPS Growth
- TGTX N/A
- ONTO 20.58
- EPS
- TGTX 0.36
- ONTO 4.04
- Revenue
- TGTX $454,069,000.00
- ONTO $1,036,353,000.00
- Revenue This Year
- TGTX $84.00
- ONTO $3.11
- Revenue Next Year
- TGTX $39.26
- ONTO $11.98
- P/E Ratio
- TGTX $81.62
- ONTO $26.85
- Revenue Growth
- TGTX 30.96
- ONTO 15.51
- 52 Week Low
- TGTX $21.11
- ONTO $85.88
- 52 Week High
- TGTX $46.48
- ONTO $228.42
- Technical
- Relative Strength Index (RSI)
- TGTX 42.03
- ONTO 58.38
- Support Level
- TGTX $27.23
- ONTO $103.61
- Resistance Level
- TGTX $28.85
- ONTO $109.02
- Average True Range (ATR)
- TGTX 1.11
- ONTO 4.12
- MACD
- TGTX 0.29
- ONTO 0.53
- Stochastic Oscillator
- TGTX 99.05
- ONTO 79.41
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.